0000049071-21-000019.txt : 20210108 0000049071-21-000019.hdr.sgml : 20210108 20210108170505 ACCESSION NUMBER: 0000049071-21-000019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210108 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20210108 DATE AS OF CHANGE: 20210108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 21518226 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 8-K 1 humform8k01082021.htm HUM FORM 8-K DATED JANUARY 8, 2021
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 8, 2021 (January 8, 2021)
 
 
Humana Inc.
(Exact Name of Registrant as Specified in Charter)
 

Delaware
001-05975
61-0647538
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

500 W. Main Street, Louisville, Kentucky 40202
(Address of Principal Executive Offices, and Zip Code)

(502) 580-1000
Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
  
 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 
 
Humana Common
HUM
New York Stock Exchange
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at an industry conference and various other meetings on January 11, 2021. During the conference and meetings, the Company intends to address its prospects and performance. The Company will not opine on any financial results or expectations for 2020 or 2021 at the meetings beyond those listed below since it is in the process of closing its books for 2020. The date and time of presentations to investors are available via the Investor Relations calendar of events on Humana’s web site at www.humana.com, and the Company’s presentation during the conference on January 11, 2021 is expected to be webcast.

Full-Year 2021 Enrollment Projections

Based on final annual enrollment period (“AEP”) results, the Company is increasing its net membership growth estimate for its individual Medicare Advantage products for the year ended December 31, 2021 to a range of 425,000 to 475,000 members from the previous range of 350,000 to 400,000 members. This membership estimate represents expected net membership gains of approximately 11 to 12 percent above the year ended December 31, 2020 membership level of approximately 3.9 million members.  The revised estimate is attributable to better than anticipated sales and member retention estimates.

In addition, the Company is updating its estimate for group Medicare Advantage net membership losses for the same period, now projecting a decrease of approximately 50,000 members year over year, compared to its previous estimate of a loss of approximately 45,000 members. This update results from slightly fewer members expected in a newly acquired large account.

For PDP, the Company now estimates a net membership decline of approximately 300,000 members for the year ended December 31, 2021, compared to its previous estimate of a loss of approximately 350,000 members. The PDP membership losses expected in 2021 are primarily the result of the Walmart Value plan not being the low cost leader in 2021. As previously disclosed, the Walmart Value plan is priced in a similar range to other low premium plans with competitive benefits. However, one plan sponsor is an outlier with an offering priced well below the rest of the market. The revised PDP membership projection is attributable to both better than expected sales and member retention estimates.

Full Year 2020 Adjusted EPS Guidance

For the year ended December 31, 2020, Humana’s management intends to reaffirm its guidance range of $24.70 to $24.95 in diluted earnings per common share (“EPS”), or a range of $18.50 to $18.75 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2020 (“FY 2020”). FY 2020 EPS guidance reflects fourth quarter 2020 losses of approximately $2.55 EPS, or approximately $2.40 in Adjusted EPS. This guidance is consistent with the guidance issued in Humana’s press release dated November 3, 2020 and reaffirmed on January 5, 2021.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company’s ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company’s business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

Diluted earnings per common share
FY 2020 Guidance
4Q 2020 Guidance
GAAP
$24.70 - $24.95
($2.55)
Amortization of identifiable intangibles
~0.51
~0.15
Put/call valuation adjustments associated with the Company’s non-consolidating minority interest investments
0.37
-
Change in fair market value of publicly-traded equity securities
 (3.73)
-
Receipt of commercial risk corridor receivables previously written off, net
(3.35)
-
Adjusted (non-GAAP) – FY 2020 and 4Q 2020 projected
$18.50 to $18.75
($2.40)

Revenue, Medical Costs and Full Year 2021 Adjusted EPS Guidance Discussion

The Company also intends to reiterate its 2021 Adjusted EPS guidance midpoint representing percentage growth modestly above its targeted long-term EPS growth rate of 11-15 percent, off of the $18.50 2020 baseline, while acknowledging the heightened uncertainty surrounding the ongoing pandemic. In reiterating this guidance range, the Company recognizes that it will take at least several months to both ascertain from CMS the negative impact to 2021 revenue growth expectations resulting from decreased utilization experienced in 2020, including in particular, the unanticipated depression in non-COVID utilization in the final two months of 2020, and the extent to which this reduction in utilization and associated medical cost impact (net of COVID related expenses) persists into 2021.  These offsetting factors continued to evolve in the final months of 2020, as described more fully below.

Beginning in the latter half of November and accelerating throughout the month of December, the Company experienced a significant increase in COVID admissions in nearly all of the markets in which it operates across its Medicare Advantage, Medicaid, and group commercial insurance business lines.  This recent surge in COVID admissions has resulted in an increased estimate of full year 2020 COVID testing and treatment costs, now expected to be approximately $1.5 billion, as compared to the Company’s previous estimate of approximately $1 billion.  The Company has also seen a corresponding decline in non-COVID utilization in all service categories, with Medicare non-COVID utilization currently running approximately 15 percent below normal levels, well below the near baseline levels of utilization witnessed as late as the end of October 2020.

As communicated since the pandemic began, the Company expects a revenue growth headwind in 2021 as a result of the decreased utilization experienced in 2020. While the Company worked tirelessly throughout 2020 to ensure members had access to and were receiving the appropriate level of care, including by significantly increasing in-home and video telehealth clinician visits, the meaningful drop in non-COVID medical utilization in recent months was not anticipated and, as such, the Company will likely experience a greater reduction in expected 2021 revenue growth than previously assumed, which could be material.

However, the Company now also expects that potentially meaningful lower non-COVID medical utilization compared to baseline may continue through at least the first few months of 2021. This is anticipated to result in lower medical costs (net of COVID related expenses) for 2021 than the Company had previously projected, which, like the revenue growth headwind discussed above, could be material.

As utilization levels return to a normal baseline and members engage in more routine non-COVID interactions with their providers, the related revenue impact is expected to normalize for the following plan year.  The Company currently anticipates that utilization will return to baseline levels throughout 2021, assuming successful rollout of COVID-19 vaccines in 2021, resulting in more normalized medical costs and revenue expectations for 2022.

Finally, the Company notes that it faces a headwind resulting from the recent increase to the Physician Fee Schedule rates for 2021, which will be partially offset by the Medicare sequester relief extension through March 31, 2021.  Both of these items resulted from the Bipartisan-Bicameral Omnibus COVID Relief Deal, dated December 20, 2020. The Company’s current estimate of the impact of these items has been contemplated in the FY 2021 Adjusted EPS guidance commentary provided above.

The Company plans to host a conference call and announce its financial results for the fourth quarter and year ended December 31, 2020, as well as provide detailed financial guidance for the year ended December 31, 2021, on Wednesday, February 3, 2021.

Cautionary Statement

This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, generally including the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions that are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the Company’s SEC filings.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.
 
BY:
 /s/ Cynthia H. Zipperle
 
Cynthia H. Zipperle
 
Senior Vice President, Chief Accounting Officer and Controller
(Principal Accounting Officer)

Dated: January 8, 2021

EX-101.SCH 2 hum-20210108.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 hum-20210108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 4 hum-20210108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 humform8k01082021_htm.xml IDEA: XBRL DOCUMENT 0000049071 2021-01-08 2021-01-08 false 0000049071 8-K 2021-01-08 Humana Inc. DE 001-05975 61-0647538 500 W. Main Street Louisville KY 40202 502 580-1000 false false false false Humana Common HUM NYSE false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Jan. 08, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 08, 2021
Entity Registrant Name Humana Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-05975
Entity Tax Identification Number 61-0647538
Entity Address, Address Line One 500 W. Main Street
Entity Address, City or Town Louisville
Entity Address, State or Province KY
Entity Address, Postal Zip Code 40202
City Area Code 502
Local Phone Number 580-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000049071
Title of 12(b) Security Humana Common
Trading Symbol HUM
Security Exchange Name NYSE
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://humana.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports humform8k01082021.htm hum-20210108.xsd hum-20210108_lab.xml hum-20210108_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "humform8k01082021.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "humform8k01082021.htm" ] }, "labelLink": { "local": [ "hum-20210108_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hum-20210108_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hum-20210108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hum", "nsuri": "http://humana.com/20210108", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "humform8k01082021.htm", "contextRef": "c20210108to20210108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://humana.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "humform8k01082021.htm", "contextRef": "c20210108to20210108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://humana.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0000049071-21-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000049071-21-000019-xbrl.zip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